The company’s profit margin doubled on the year to 9.7%, considering that the increase was not significant, in terms of sales.
Fiterman Pharma’s portfolio includes some 135 products, from prescription drugs, over-the-counter drugs to cosmetics and medical devices, per data on the company’s website.
The Fiterman family is one of the richest in the Romanian region of Moldavia and also controls the Arcadia medical group inaugurated in 2010, following an investment of EUR20 million. Arcadia, which operates several clinics and a hospital, posted a consolidated turnover of RON106.6 million in 2019, up 13% on the year.
Fiterman Pharma shareholders include Solomon Fiterman (43.6%), Mara Fiterman (27.9%), Dan Fiterman (13.8%) and Patricia Fiterman (13.8%), per data on confidas.ro platform.
On the Romanian market, Fiterman Pharma competes against pharmaceuticals producers such as Terapia Cluj, Zentiva Bucuresti, Antibiotice Iasi, but the COVID-19 pandemic has put pressure even on the medical drug manufacturing industry, one of the few industries operating during the period of travel bans.
Total medical drug sales in Romania reached RON17.8 billion in 2019, per data from market research firm Cegedim.